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Abstract: Early diagnosis and prevention is a key factor in reducing the mortality and morbidity of cancer. However, 
currently available screening tools lack enough sensitivity for early diagnosis. It is important to develop noninvasive 
techniques and methods that can screen and identify asymptomatic patients who have cancer. Biomarkers of cancer status 
can also serve as powerful tools in monitoring the course of cancer and in determining the efﬁ  cacy and safety of novel 
therapies. Thus, discovery of novel speciﬁ  c biomarkers are needed that may provide informative clues for early diagnosis 
and treatment of cancer. Recently, remarkable progress has been made in the development of new proteomics technology. 
The progress that has been made in this ﬁ  eld is helpful in identifying biomarkers that can be used for early diagnosis of 
cancer and improving the understanding of the molecular etiological mechanism of cancer. This article describes the cur-
rent state of the art in this ﬁ  eld.
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Introduction
Cancer is the second leading cause of death in the United States (1). It is estimated that more than 
11 million people are diagnosed with cancer every year (1). This number is estimated to rise to 16 million 
every year by 2020 (1). Early diagnosis and prevention are key factors needed to reduce the mortality 
and morbidity of all types of cancer. Unfortunately, currently available cancer screening tools (e.g. 
mammography and invasive needle or surgical evaluation for breast cancer; or chest X-ray for lung 
cancer, etc.) are not sensitive enough for early detection of the disease. It is imperative to develop non-
invasive techniques that distinguish between patients with and without cancer, as well as between stages 
of cancer.
Recently, genomic and proteomic technologies have evolved rapidly in cancer research. Genomic 
technologies allow us to monitor thousands of gene expression proﬁ  les simultaneously and evaluate 
interactions of candidate genes to obtain a global view of cancerous tissue in a single unbiased 
experiment. Despite its ubiquity and remarkable usefulness, microarray technology has technical 
limitations because transcriptional regulation is often difﬁ  cult to reconcile with protein abundance, 
and the transcriptome poorly correlates with the proteome in a cell (2,3). Proteomics studies allow us 
to understand proteins and their modiﬁ  cations which may not be reﬂ  ected by analysis of gene expres-
sion. The proteome contains all of the gene products that represent the functional output of a cell rather 
than nucleic acids that are derived from an individual’s full genetic code. Proteomics has now gained 
more attention because by directly analyzing protein expression at the post-translational level, it per-
mits the qualitative and quantitative assessment of a broad-spectrum of proteins that can be related to 
speciﬁ  c cellular responses (4–6). Proteome analysis provides useful clues to biological processes hap-
pening at their level of occurrence, allowing comparison of physiological and pathological states of 
a cell line or a tissue. Further, proteomics, as a “new genomics”, can be used not only to study expres-
sion proﬁ  ling of the whole cell, but also can apply to study of cellular compartments and organelles 
and their time-resolved dynamics (7).64
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Proteomics as a Powerful
Biomarker Screening Tool
Proteomics is the large-scale study of proteins, 
particularly their structure and functions, including 
detection, identiﬁ  cation, measurement of their 
concentration, characterization of modiﬁ  cation, 
characterization of protein-protein interaction and 
regulation. This term was coined to make an anal-
ogy with genomics  , but it   is much more compli-
cated than genomics. Most importantly, while the 
genome is a rather constant entity, the proteome   is 
a rather dynamic entity and differs from cell to cell. 
The proteome in cells is constantly changing 
through its biochemical interactions with the 
genome and the environment. With completion of 
a rough draft of the human genome, many research-
ers are now focusing on how genes and proteins 
interact to form other proteins. It is estimated that 
the human proteome consist of 500,000 proteins 
derived from about 35,000 genes in the human 
genome. The large increase in protein diversity 
may be due to alternative splicing (8,9) and post-
translational modiﬁ  cation (10,11) of proteins. This 
discrepancy implies that protein diversity cannot 
be fully characterized by gene expression analysis 
alone, making proteomics   a promising tool for 
characterizing cells and tissues of interest and for 
biomarker discovery. In addition, some proteins 
may be expressed during very short periods of time 
in the life of an individual, while others may be 
continually expressed but with half lives too short 
to be isolated and detected (12). Therefore, 
although much effort has been devoted to bio-
marker discovery in clinical research, few effective 
biomarkers are available for early diagnosis of 
cancer (Table 1). In this communication, we will 
summarize advances in proteomics that might be 
used for efﬁ  cient and effective cancer biomarker 
discovery. We will also attempt to shed light on 
future directions of proteomics research for cancer 
biomarker discovery.
Qualitative Proteomics
Proteomics research includes the characterization 
of protein mixtures in order to understand complex 
biological systems and determine relationships 
among proteins, their functions, and protein-
protein interactions. Generally, proteomics can be 
characterized as qualitative proteomics and quan-
titative proteomics. Qualitative proteomics exper-
iments aim to study changes in protein expression (13). 
Mass spectrometry (MS)-based quantitative 
proteomics has become an increasingly popular 
approach to study changes in protein abundances 
and diversity in biological samples. Qualitative 
proteomics aims to monitor changes in protein 
mixture composition under different physiologi-
cally relevant conditions (14). Similar to genomics 
study, a classic qualitative proteomics study com-
pares the relative levels of thousands of protein 
species in different biological samples by standard 
protein proﬁ  ling technologies, such as protein 
microarrays, 2-DE, 2-DLC. Taking advantage of 
the genome sequence database, query algorithms 
and newly-developed mass spectrometry instru-
ments, qualitative proteomics has been enhanced 
in characterizing the molecular mechanisms of 
diseases (15–17). Quantitative proteomics provides 
quantitative information for all proteins in a 
sample instead of only providing lists of identiﬁ  ed 
proteins (18–19). It aims to discover differences 
between samples (e.g. healthy and diseased patients). 
The methods of protein identiﬁ  cation are identical 
to those used in qualitative proteomics, but include 
quantiﬁ  cation as an additional dimension.
Two dimensional gel electrophoresis
Two-dimensional gel electrophoresis (2DE) is one 
of the most common proteomics technologies with 
relative low resolution and simple technique. 
Proteins are separated ﬁ  rst based on charge across 
a deﬁ  ned PH gradient in one direction and then 
separated by mass in another vertical direction. It 
allows us to monitor thousands of proteins simul-
taneously in a semiquantitative manner and to 
detect the protein components of each spot by 
identifying discriminating spots from the gels 
robotically and analyzing their sequence by tandem 
mass spectrometric methods (4,5,20,21). 2D gel 
analysis is the most well established standard for 
protein proﬁ  ling of complex protein mixtures. The 
most notable limitation is that 2-DE requires rela-
tively large amounts of sample material and can 
only identify the most abundant proteins.
14
Two dimensional liquid
chromatography
Although gel-based proteome proﬁ  ling has been 
widely used for protein separation, it suffers from 
several signiﬁ  cant shortcomings such as lack of 
throughput potential and reproducibility as well as 
difﬁ  culties in resolving proteins that are highly 
basic, or of high molecular weight, or in low 65
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Table 1. Summary of the tumor biomarkers identiﬁ  ed by using proteomics.
Cancer type Biomarker Reference Primary 
clinical use
Status Sensitivity Speciﬁ  city
Bladder cancer NMP22 (12) Disease
monitoring
Validated Low High
Breast cancer CA15-3 (13) Disease
monitoring
Validated Moderate Poor
CA27-29 (14) Disease
monitoring
Validated - -
CEA (15) Disease
monitoring
Validated - Low
Her2/Neu (16) Disease
monitoring
Validated - Moderate
Colorectal cancer CEA (17) Disease
monitoring
Validated Moderate Low
Esophageal Periplakin (18) Disease
monitoring
Validated - -
Gastrointestinal
stromal tumor
CA19-9 (19) Disease
monitoring
- Poor
Hepatocellular
carcinoma
α-fetoprotein (20) Staging Validated - Moderate
Leukemia HnRNPs (21) Disease
monitoring
Putative - -
Lung cancer CEA (22) Disease
monitoring
Validated Low
Epidermal GFR (23) Selection of 
therapy
Validated Low
Cyfra21-1 (24) Disease
monitoring
Validated High Very high
Lymphoma Histone H4 (25) Disease
monitoring
Putative - -
Nasopharyngeal
carcinoma
Serum amyloid A (26) Diagnosis Putative - -
Ovarian cancer Human chrionic 
gonadotropin-β
(27) Staging Validated - Low
Apolipoprotein A1 (28) Diagnosis Putative - -
Heptaglobin
α-subunit
(29) Diagnosis Putative - -
CA-125 (30) Diagnosis Putative -
Transthyretin 
fragment
(31) Diagnosis Putative - -
Osteopotin (32) Diagnosis Putative - -
Pancreatic cancer CA19-9 (33) Disease
monitoring
Validated High Poor
α1-antitrypsin and 
α1-antichymotrypsin
(34) Diagnosis Putative - -
Apolipoprotein A1 (35) Diagnosis Putative - -
Heptaglobin α-
subunit
(36) Diagnosis Putative - -
Prostate cancer PSA (37) Selection of 
therapy
Validated High High
Vitamin D-binding 
protein
(38) Diagnosis Putative - -
Osteopotin (39) Diagnosis Putative - -
Renal cancer Serum amyloid alpha (40) Disease
monitoring
Putative - -
Liver AFP (41) Diagnosis Validated Moderate -66
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abundance (22–25). To circumvent problems 
associated with 2-DE, several liquid-phase 
separation methods (26), such as size-exclusion 
chromatography (27), afﬁ  nity chromatography (28) 
and ion-exchange chromatography (29) have been 
developed.
Combinations of the different liquid-phase 
separation methods can be formed for multiple 
dimensional liquid chromatography that are suitable 
for separation of the whole cellular proteome   as 
well as the plasma proteome. Recently, a new 
multidimensional liquid chromatographic separation 
system (M-D LC) has been developed by combining 
chromatofocusing (CF) (30–32) and nonporous 
reverse phase column chromatography 
(NPRPC) (32–34). This new method can provide 
greater throughput potential for reproducible 
separation of complex mixtures in mammalian cells 
such as those in mouse macrophage cell lines (32–34). 
This method has some advantages such as high 
reproducibility between batches, but quantitative 
measurement of protein abundance in a sample 
remains a challenge.
Quantitative Proteomics
While monitoring qualitative changes is valuable, We 
also need to develop quantitative tools that can pro-
vide deep insight into disease mechanisms in order 
to unveil key molecules that may play major roles in 
disease processing. Enabled by the advent of quan-
titative proteomics technologies, rapid advancements 
in global detection and quantitation of proteins have 
provided an enormous set of both opportunities and 
challenges to discover molecular mechanisms of 
cancer and other diseases. Great interest has been 
directed toward characterization of cell function (15), 
disease mechanism (16) and biomarker discovery (35). 
Recently, quantitative proteomics has been achieved 
by development of new strategies that use metabolic 
or post-extraction stable-isotope labeling alone, or in 
combination with afﬁ  nity tags (12,36–38). In this 
section, we will summarize the development of quan-
titative proteomics methods.
Radioactive labeling
Radioactive labeling is the most sensitive and 
reliable method to detect cellular protein dynamics. 
Brieﬂ  y, protein is labeled with (35) S (39–40) 
or (32) P isotopes (41,42) and separated on 2-D 
gel. Labeled protein in the gel is then exposed to 
a storage phosphor screen, which is subsequently 
scanned with a laser. The protein detection limit is 
less than 1 pg. However, there is a trend toward 
replacing the radioactive material by using other 
labeling methods to avoid problems with radiation 
safety in the laboratory.
Fluorescence labeling
To get similar sensitivity to radioactive labeling, 
fluorescence labeling provides a non-isotopic 
approach to study dynamic proﬁ  ling of the pro-
teome in cells or tissue. This labeling assay 
includes two-dimensional differential gel electro-
phoresis (2-DDGE).
Two-dimensional difference gel 
electrophoresis (2-DDGE)
2-DDGE is a protein differentiation technology 
that can execute a type of differential comparison 
of a given protein state in reference to a control. 
2-DDGE differs from classic 2-DE in that the 
CyDye technology allows multiplexing a proteome  
display in one gel. This technology is not only a 
detection technique, but also offers a method for 
accurate quantitative proteomics  . Using CyDye 
technology, different protein samples can be pre-
labeled with dyes of different excitation and emis-
sion wavelengths, then mixed and run together in 
a single gel (14). Differentially expressed proteins 
can be subsequently identiﬁ  ed by mass spectro-
metric methods. Although this technique shows 
some advantage in reducing gel-to-gel variation 
while compared to 2-DE, it also shows certain 
limitation for separation of proteins with high 
molecular weight, various hydrophobicity and 
extreme pI vaules.
Stable-isotope labeling
Stable-isotope labeling can be classiﬁ  ed as two 
types of methods, namely, chemical labeling and 
metabolic labeling in the living cell. The Chemical 
labeling method includes isotope-coded afﬁ  nity 
tag   (ICAT) technology (43–46) and isobaric tags 
for relative and absolute quantiﬁ  cation (iTRAQ) 
(47–50). Metabolic labeling in living cells includes 
stable isotope labeling with amino acids in cell 
culture (SILAC) (48–50).
Isotope-coded afﬁ  nity tags   (ICAT)
ICAT, ﬁ  rst developed by Aebersold and his col-
leges (36), is an innovative method of protein 67
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proﬁ  ling that utilizes stable isotope labeling of 
protein samples from two different sources, which 
are chemically identical in all aspects other than 
isotope compositions. ICAT analysis proﬁ  les the 
relative amounts of peptides containing cysteine 
that are derived from tryptic digests of protein 
extracts. Proteins extracted from the two samples 
are labeled with either light or heavy ICAT reagents, 
and react via cysteinyl thiols on the proteins. Pep-
tides are recovered by avidin afﬁ  nity chromatog-
raphy and are then analyzed by LC-MS-MS. This 
produces a full scan spectrum which displays the 
abundance of light and heavy peptide ions and their 
relative proteins.
The signiﬁ  cance of ICAT technology is that it can 
be used to identify 300–400 proteins per sample 
without using the 2-D gel (43). Also, enrichment of 
low-abundance proteins can be performed before the 
analysis through cell lysate fractionation (44). ICAT 
technology has been widely used for protein 
identiﬁ  cation and quantiﬁ  cation in mammalian, liver 
and breast tumor cells (43). Disadvantages of ICAT 
analyses are; they are only applicable to proteins 
containing cysteine; they identify far fewer proteins 
than 2-DE; and they contain a large label, which 
makes database searching more difﬁ  cult, especially 
for short peptides (44).
Isobaric tags for relative and absolute 
quantiﬁ  cation (iTRAQ)
iTRAQ have been newly developed by Ross 
et al (48) and ﬁ  rst introduced by Applied Biosys-
tems (Applied Biosystems, Framingham, USA). 
This method is used for multiplexed quantitative 
proteomic analysis (48) and applied to different 
applications of proteome proﬁ  le analysis (45,49,50). 
The principle for iTRAQ is to use a set of isobaric 
reagents which are amine speciﬁ  c to identify and 
quantify simultaneously up to four different sam-
ples. The amine speciﬁ  city of these reagents makes 
most peptides in a sample amenable to this labeling 
strategy with no loss of information from samples 
involving post-translational modiﬁ  cations, such as 
phosphorylation. In addition, the multiplexing 
capacity of these reagents allows for information 
replication within certain LC-MS/MS experimen-
tal regimes, providing additional statistical valida-
tion within any given experiment. However, this 
is a chemical labeling method, which might gener-
ate side products during labeling and cause some 
loss of analytic sensitivity. Therefore, it may be 
only suitable for mass spectrometry validation of 
biomarker candidates. It may not be suitable for 
proteome dynamic proﬁ  ling studies.
Stable isotope labeling with amino acids 
in cell culture (SILAC)
SILAC has become a popular labeling strategy for 
peptide quantitation in proteomics experiments. It 
is a simple approach that incorporates a label into 
proteins for mass spectrometry (MS)-based quan-
titative proteomics in vitro. It was ﬁ  rst developed 
by Mann et al (51) based on metabolic incorpora-
tion of a given ‘light’ or ‘heavy’ form of the amino 
acid into the proteins in living cultured cells. The 
method relies on the incorporation of amino acids 
with substituted stable isotopic nuclei (e.g. deute-
rium, 
13C, 
15N, 
18O). Thus in an experiment, two 
cell populations are grown in culture media that 
are identical except that one of them contains a 
‘light’ and the other a ‘heavy’ form of a particular 
amino acid (e.g. 
12C and 
13C labeled L-lysine, 
respectively) (Fig. 1). When the labeled analog of 
an amino acid is supplied to cells in culture instead 
of the natural amino acid, it is incorporated into all 
newly synthesized proteins. After a number of cell 
divisions (2 or more), each instance of this par-
ticular amino acid will be replaced by its isotope 
labeled analog. Since there is little chemical dif-
ference between the labeled amino acid and the 
natural amino acid isotopes, the cells behave 
exactly like the control cell population grown in 
the presence of normal amino acids. It is efﬁ  cient 
and reproducible as the incorporation of the isotope 
label is 100%. This is a promising pioneer tech-
nique that can be used for characterization of 
phenotype-associated cellular signaling transduc-
tion. It is now being extensively applied for bio-
marker discovery (35), cell signaling dynamics (52), 
identiﬁ  cation of posttranslational modiﬁ  cation 
sites (53,54), protein-protein interaction (55–57) 
and subcellular proteomics (58).
Gronborg et al. have used this strategy to study 
the differential secreted proteome in the case of 
pancreatic cancer (35). A human pancreatic ductal 
epithelial cell line was grown in normal media and 
the pancreatic cancer cell line was grown in media 
supplemented with heavy isotopic forms of argi-
nine and lysine (
13C6). The media were harvested, 
and proteins were resolved on a SDS PAGE. LC-
MS/MS was further carried out following trypsin 
digestion. They successfully identified five 68
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conﬁ  rmed proteins (CD9, perlecan, SDF4, apoE, 
and ﬁ  bronectin receptor) as potential biomarkers 
that may be used for diagnosis of pancreatic can-
cer (35). A similar approach was employed by 
Yocum et al. to investigate possible protein signa-
tures in different MLL leukemias in order to iden-
tify disease biomarkers and protein targets for 
pharmacological intervention using MV4 -11 and 
RS4:11 cells in culture (59). The majority of bio-
markers and drug targets are membrane associated 
proteins. Recently, Liang et al. used SILAC to 
perform differential membrane proteomics in 
breast cancer cells to identify proteins that are dif-
ferentially expressed on the surface of a breast 
cancer cell when compared to its normal counter-
part (60). They have quantiﬁ  ed 1600 gene products 
that group into 997 protein families with approxi-
mately 830 membrane or membrane-associated 
proteins. This study demonstrated that SILAC, a 
powerful technique, can be potentially useful for 
the discovery of membrane-bound antigens in 
phenotype-associated studies (60).
Perspectives
Qualitative proteomics has provided very valuable 
information for understanding biological problems 
in the past decade. Proteomics technologies are the 
most important and useful approaches to observe 
and identify biomarkers with signiﬁ  cant clinical 
meaning in cancer research. Protein biomarkers 
identiﬁ  ed, for example, will help to improve the 
early diagnosis of cancer, provide a tool to monitor 
response to treatment and enhance the quality of 
patient administration (61). Protein biomarkers 
identiﬁ  ed can also serve as therapeutic targets and 
provide mechanistic approach for effective drug 
design (61). Proteomics, however, still has many 
Figure 1. A schematic representation of the SILAC (‘stable-isotope labelling in cell culture’) method. A stably labelled amino acid in a cell-
culture medium (in this case, ‘heavy’ arginine or lysine) is incorporated fully into the proteome of one cell population (“Cell pop 2”). Relative 
quantiﬁ  cation experiments can easily be carried out using cells that were grown in normal media as the control (Cell pop 1). Cell lysates 
from two conditions can be combined and puriﬁ  ed through many steps. The proteins are then digested and if the two forms of the peptides 
co-elute, a peptide ratio can be obtained for each mass spectrum, which allows the protein levels in the two populations to be quantiﬁ  ed 
relative to each other.69
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challenges in discovering tumor biomarkers. The 
challenge raised by quantitative proteomics is how 
best to identify large numbers of proteins from 
complex biological samples (Table 2). The multi-
step method appeared as a potentially powerful 
technique for large quantitative and qualitative 
proteomics research. Complex biological samples 
can be effectively divided into the relevant identi-
fication of increasing numbers of proteins. 
Currently, the major challenge is how to identify 
diagnostic patterns speciﬁ  c to cancer states from 
the huge dynamic range of biomarker concentra-
tion and biological variability among patient 
samples. For example, variation in sample collec-
tion, handling or storage and proﬁ  ling techniques 
may inﬂ  uence the protein proﬁ  le obtained from a 
given sample. So it is critical to solve and resolve 
these problems in biological variation, pre-
analytical variation and analytical variability. It is 
increasingly recognized that routine proteomic 
analysis should be applied in the clinical setting to 
enhance reproducibility and validation of tumor 
biomarkers.
The popular iTRAQ method
48 is a novel method 
that can offer quantitative measure of the cell pro-
teome. In summary, this method can: 1) improve 
overall protein and proteome coverage while 
retaining important post translational modiﬁ  cation 
information, 2) simultaneously compare multiple 
samples, e.g. normal versus diseased versus drug 
treatment samples, or apply to time course studies, 
all in the same experiment, 3) quantify and validate 
speciﬁ  c proteins of interest, such as biomarkers, 
or to screen drug targets and 4) increase statistical 
relevance needed for quantitative experiments by 
expanded multiplexing, up to four, to include 
duplicates or triplicates in the design. This is a 
chemical labeling method that can be quantitatively 
used for biomarker validation. Although iTRAQ 
can be done on any proteome including body ﬂ  uids 
and biopsy material, it might also introduce side 
products (false positive results) that limit the sen-
sitivity of the analysis since chemical strategies 
involve a derivatization step that might not be 
complete.
The SILAC method seems to be promising for 
study of biomarker discovery since it is based on 
metabolic labeling strategy in living cells. It offers 
a few advantages: 1) the expected mass difference 
is known before peptide identiﬁ  cation, thus sim-
plifying the quantitation, 2) mammalian cells are 
easily labeled by providing SILAC amino acids 
other than eliminating any unlabeled nitrogen 
source (e.g. if 
15N is used) from the cultured 
medium, 3) a high degree of labeling since only 
one or two amino acids in a peptide can be substi-
tuted, 4) technically, quantitation is simpliﬁ  ed and 
straightforward (64). Although the traditional iso-
tope labeling method can not provide protein 
synthesis information, this approach allows for the 
determination of changes in protein expression 
levels of all cellular proteins by determining the 
mass spectral peaks corresponding to the unlabeled 
(from manipulated cells) to labeled (from control 
cells) protein as illustrated in equation (1).
  Protein expression = 
[unlabeled peak]
[labeled peak].
 (1)
A ratio of one means that protein is neither 
under- nor over-expressed. A ratio of 1 means 
under-expression (concentration is less than that of 
the control) and 1, over-expression (concentration 
is greater than that of the control). Because the 
doses used in this cell culture system (e.g. deuterium 
water used is 4%) are much higher than that 
usually used in the clinic (e.g. deuterium dose is 
2%), application of this technology for clinical 
study has certain limitations. The existing algorithms 
of SILAC are incapable to handle such complex 
data generated from mass spectrometry in clinical 
patient study (65). To overcome the disadvantages 
mentioned-above, it is more important to improve 
analytic algorithms of MS data analysis. 
Interestingly, a recent patient study using deuterium 
water as a tracer suggests a promising algorithm 
for simplifying analysis of sophisticated MS data  (65). 
This method, “modiﬁ  ed SILAC (mSILAC)”, can 
measure protein synthesis rate quantitatively and 
protein turnover based on mass isotopmer distribution 
(MIDA) (65). The method can be applied to a large 
number of proteins (either known or unknown) in 
cells or tissues. This could improve the SILAC 
method that is used for the study of cell biology, 
including biomarker discovery.
In the future, a major concern will be about how 
to integrate effectively the proteomic with genomic 
and metabolomic, data and their functional inter-
pretations in clinical results. In data analysis of 
proteomics in cancer research, with the rapid 
increase in cancer research dealing with datasets, 
exhaustive searching can not guarantee ﬁ  nding the 
best subset from the large numbers of variables. 
That means, statistically, we can exhaustively 70
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Table 2. Summary of proteomics approaches for tumor biomarker discovery.
Approach 
type
Approach Advantages Disadvantages Reference
Qualititative 
Analysis
Protein 
microarray
>   good for unknown protein 
functional assay
> high throughput
> limited information
> relative expensive
(14)
2-DE >   simultaneously monitor thousands 
of proteins
>   compatible with various stain 
methods
> high throughput
>   require relatively large 
amounts of starting 
material
>   only identify the most 
abundant proteins
>   not good 
reproducibility
(14)
2-D LC > greater throughput potential
> good reproducibility
> easy conﬁ  gure to MS analysis
> difﬁ  culty data analysis
> nonquantitative
> relative expensive
(32–34)
MS-based 
proteomics
> highly sensitive
> relative simple protocol
>   posttranslational modiﬁ  cation 
analysis
> nonquantitative
>   too many redundant 
sequence
(62)
Quantitative 
Analysis
Radioactive 
labeling
> highly sensitive
> very good quantitative
>   posttranslational modiﬁ  cation 
analysis
> safety (39–42)
Fluorescence 
labeling
> highly sensitive
> reduced 2-DE variation
> compatible with MS analysis
> expensive
>   marginal reproducibility
>   only good for high 
abundance proteins
(14,63)
ICAT > highly sensitive
> good quantitative
> limited application
> difﬁ  culty data analysis
(44,36)
iTRAQ > good proteome coverage
>   simultaneously comparison of 
multiple samples
> good statistic relevance
>   good quantitative and good for 
biomarker validation
> possible false positive
>   reduced sensitivity 
because of chemical 
labeling
(48)
SILAC >   known expected mass difference 
prior to identiﬁ  cation, simple 
quantition
>   highly labeling yield, easily 
labeling in mammalian cells
>   protocol simple and 
straightforward
> highly sensitive
> potential application in vivo study
>   difﬁ  culty data analysis 
for low or partially 
labeled species
(35, 51–61, 
64)
mSILAC >   known expected mass difference 
prior to identiﬁ  cation, simple 
quantition
>   highly labeling yield, easily 
labeling in mammalian cells
>   protocol simple and 
straightforward
> highly sensitive
>   application for in vivo and cell 
culture studies
> to be validated (65)71
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search all the potential combinations of the 
proteomic, genomic and metabolomic data, but one 
cannot guarantee all the combinations are true 
positive since there are multiple testing problems 
here if we want to test the “best” subset from large 
numbers of variables. Second, different variables 
may have interactions among them, thereby we 
need to develop robust multivariate method in order 
to investigate the correlations between different 
dataset and different variable within one dataset. 
Certainly, univariate approaches cannot handle the 
correlations between variables, resulting in losing 
important discriminatory information. Multivariate 
analysis and other approaches must be applied in 
the data analysis used in proteomics.
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